Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

Both Mounjaro and Zepbound have the same active ingredient ... It is also looking to expand commercial access to its GLP-1 drugs and expects improvements in 2025, particularly with Medicare ...

Most economists expect muted U.S. economic growth in the coming quarters, and some indicators suggest a mild U.S. recession is still a possibility. It may become difficult for investors to ...

Zepbound® (tirzepatide ... In 2025, Ms. Walker will collaborate with Lilly on certain digital commercial activities. Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Trump directed a panel headed by HHS Secretary Robert F. Kennedy Jr. to assess “the prevalence of and threat” posed by SSRIs, ...